3 days Ago By ABMN Staff
Allogene Therapeutics, Inc. ( NASDAQ:ALLO – Get Free Report ) saw a large drop in short interest in October. As of October 31st, there was short interest totalling 37,040,000 shares, a drop of 5.
8% from the October 15th total of 39,320,000 shares. Based on an average trading volume of 1,980,000 shares, the short-interest ratio is presently 18.7 days.
Currently, 26.7% of the company’s stock are sold short. Wall Street Analyst Weigh In ALLO has been the subject of a number of analyst reports.
Oppenheimer initiated coverage on Allogene Therapeutics in a research report on Thursday, August 8th. They set an “outperform” rating and a $11.00 price target on the stock.
Piper Sandler lowered their target price on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th.
Truist Financial reiterated a “buy” rating and issued a $14.00 price target (down previously from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th.
Canaccord Genuity Group decreased their price objective on shares of Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, August 8th.
Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Allogene Therapeutics in a report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock.
According to data from MarketBeat.com, Allogene Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $9.73.
Read Our Latest Research Report on ALLO Institutional Investors Weigh In On Allogene Therapeutics Allogene Therapeutics Stock Performance Shares of ALLO stock opened at $2.12 on Wednesday. Allogene Therapeutics has a 52 week low of $2.
01 and a 52 week high of $5.78. The company has a market capitalization of $444.
50 million, a price-to-earnings ratio of -1.36 and a beta of 0.84.
The company has a 50-day simple moving average of $2.73 and a 200 day simple moving average of $2.64.
Allogene Therapeutics Company Profile ( Get Free Report ) Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). Featured Articles Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
